We examined the interrelation between systemic hypertension, hyperlipidemia, and progressive renal injury in experimental glomerulonephritis. Induction of nephrotoxic serum nephritis in Sprague-Dawley rats led to systemic hypertension and hyperlipidemia. Four groups of rats were studied over a 16-week period: (1) untreated nephritic rats; (2) nephritic rats treated with hydralazine, reserpine, and lasix (AH); (3) nephritic rats treated with lovastatin (4 mg/kg) (Lova); and (4) nephritic rats treated with combined antihypertensive/lipidlowering therapy (AH/Lova). Systolic blood pressure rose progressively in untreated rats (152±4 mm Hg at 16 weeks ). Glomerular injury score was significantly reduced by antihypertensive therapy (P<.01) and lipid-lowering therapy (f<.05). Glomerular injury score was lowest in animals receiving combined therapy, reflecting an interaction between these therapies (P<.01) (untreated, 173±29; Lova, 128±24; AH, 111±22; AH/Lova, 48±11). Our results suggest that both hypertension and hyperlipidemia accelerate glomerular sclerosis in experimental glomerulonephritis and that combined therapy of these disorders may best limit progressive renal injury. (Hypertension. 1994^3:92-95.) Key Words • hyperlipidemia • glomerulonephritis • hypertension C omplex interrelations exist between systemic hypertension, hyperlipidemia, and progressive renal injury. Recent evidence indicates that hyperlipidemia may be associated with accelerated renal damage in experimental glomerular disease and that lipid-lowering therapy ameliorates progressive renal injury in many of these models. 13 Moreover, it has been suggested that pathogenetic mechanisms responsible for the evolution of fatty streak lesions in blood vessels are analogous to those responsible for the development of glomerulosclerosis.1 ' 2 We have previously shown that systemic hypertension exacerbates renal injury in experimental glomerulonephritis. 4 Similarly, other investigators have demonstrated acceleration of atherosclerotic vascular lesions when experimental hypertension is combined with an atherogenic diet or superimposed on hereditary hyperlipidemia. 58 We hypothesize that factors predisposing to atherosclerotic vascular lesions, most notably systemic hypertension and hyperlipidemia, may have similar importance in the development of glomerular sclerosis. In fact, several studies suggest that hypertension and hyperlipidemia may have additive or perhaps synergistic effects on the development and progression of glomerular injury, as reflected by proteinuria and glomerular sclerosis. 912 In this context, we undertook a study to determine the relative efficacy of antihypertensive and cholesterol-lowering therapy in ameliorating progressive renal injury in nephrotoxic serum nephritis in the rat, a model characterized by both hypertension and hyperlipidemia. Our results suggest that both hypertension and hyperlipidemia accelerate glomerular sclerosis in experimental glomerulonephritis and that combined therapy of these disorders best l...